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Abstract
Taurine is involved in various physiological processes, and one of the most
abundant amino acids in human. The aim was to investigate the mechanism
for intestinal absorption of taurine in vivo using also in vitro mechanistic
studies. Taurine absorption was measured in male Sprague-Dawley rats at
10–997 mg/kg and 1–30 mg/kg for oral and intravenous administration,
respectively. Oral absorption was measured in the presence of substrates for
the proton-coupled amino acid transporter, PAT1, that is, 200 mg/kg proline
(Pro) and sarcosine (Sar), and in the presence of 2-Amino-2-norbornanecar-
boxylic acid (BCH) (200 mg/kg). BCH is not an inhibitor of PAT1 or the tau-
rine transporter, TauT, hence it was included as a negative control. In vitro
studies investigating the transport mechanism of taurine were conducted in
human intestinal Caco-2 cells. The pharmacokinetic investigations showed
that intestinal taurine absorption was not saturable at the investigated doses,
but that the time (tmax) to reach the maximal plasma concentration (Cmax)
increased with dose. Furthermore, Sar and Pro, but not BCH, decreased tau-
rine Cmax. In vitro it was clearly shown that PAT1 mediated the cellular
uptake of taurine and thereby facilitated the transepithelial taurine transport,
which could be inhibited by Pro and Sar, but not BCH. In vivo and in vitro
results suggest that taurine absorption from the intestine is caused by PAT1.
Introduction
Taurine, 2-aminoethane sulfonic acid, is involved in
several biological processes; for example, serving as a pre-
cursor for the tauro-conjugated bile salts, for example,
taurocholate; for cellular volume regulation (for refer-
ences see the excellent review by Huxtable (1992)) and;
being important for retinal homeostasis through its
function as an antioxidant and osmolyte (Huxtable 1992)
(Ripps and Shen 2012). Taurine is available though both
exogenous or endogenous sources. The exogenous source
comes from oral ingestion of food, it can be found in
large amounts in, for example, meat (Huxtable 1992).
Taurine is also a component of infant formula and total
parental nutrition for infants and adults. Moreover, tau-
rine is currently a popular supplement in “high energy”
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drinks. These drinks contain an average of 3.18 g/L
taurine (Caine and Geracioti 2016), with popular brands
typically containing 4 g/L of taurine (Caine and Geracioti
2016), corresponding to an initial concentration of
32 mmol/L taurine which enters the gastrointestinal tract.
For many years, it has been known that the sodium-
chloride coupled taurine transporter, TauT, transports
taurine across plasma membranes in a symport manner
and the responsible transporter was cloned from various
species in the early 1990s (Smith et al. 1992; Uchida et al.
1992; Jhiang et al. 1993). The taurine transporter is a
high-affinity transporter with lM affinity for taurine and
a low transport capacity (Liu et al. 1992; Smith et al.
1992). However, another intestinal amino acid trans-
porter, the proton-coupled amino acid transporter, PAT1
(SLC36A1), has also been suggested to facilitate taurine
transport across intestinal cells (Thwaites et al. 1995;
Anderson et al. 2004, 2009). PAT1 has low affinities for
its substrates including taurine, that is, with mM affinities
in contrast to the lM range observed for TauT, and a
high transport capacity (Larsen et al. 2008; Nohr et al.
2014b). In 2009, Anderson et al. (2009) demonstrated
in vitro, in intestinal Caco-2 cells, that both TauT and
PAT1 contributed to cellular uptake of taurine, with
PAT1 being the major transporter at higher
concentrations.
Despite the scientific and nutritional interest in taurine
and taurine transporting solute carriers, knowledge on the
involvement of solute carriers (SLC) in oral absorption of
taurine in vivo is limited and so is knowledge of oral and
intravenous (IV) taurine pharmacokinetics. To the best of
our knowledge, pharmacokinetic studies are limited to a
few, none addressing the involvement of solute carriers;
one study has investigated taurine absorption in healthy
male human volunteers after administration of one dose
of 4 g taurine in a capsule formulation given to the sub-
jects (Ghandforoush-Sattari et al. 2010). In male Sprague-
Dawley rats, taurine pharmacokinetics have been investi-
gated after intravenous administration of 20 mg/kg
taurine (Tang et al. 2014), and in male and female Spra-
gue-Dawley rats after oral administration of 30 or
300 mg/kg taurine (Sved et al. 2007). Taurine (6 mg/kg)
has also been given intravenous to beagle dogs as a single
administration together with 0.6 mg/kg edaravone (Yu
et al. 2013). While these studies form an initial under-
standing of taurine pharmacokinetics, no systematic
investigation of dose-dependent intravenous or oral phar-
macokinetics is available. Furthermore, the role of PAT1
in mediating intestinal taurine absorption in vivo has, to
the best of our knowledge, not been investigated before.
The aim of this study was therefore to investigate the
pharmacokinetics of taurine in vivo after oral and intra-
venous administration of different taurine doses, and
furthermore to investigate if the proton-coupled amino
acid transporter PAT1 is involved in the oral absorption
of taurine in vivo. Since PAT1 knock-out animals are not
available, we used an inhibitor-based approach as previ-
ously used in the investigations of the role of PAT1 in
intestinal gaboxadol and vigabatrin absorption (Larsen
et al. 2009; Broberg et al. 2012; Nohr et al. 2014a, 2015).
This was supplemented with mechanistic investigation of
TauT and PAT1 mediated transport in vitro using intesti-
nal Caco-2 cells. Collectively, the work presented here
shows that oral absorption of taurine was not saturated
in the dose range of 10–997 mg/kg, yet the time (tmax) to
reach the maximal plasma concentration (Cmax) increased
with dose. Furthermore, Sar and Pro, but not BCH,
decreased taurine Cmax. BCH was chosen since it is not a
substrate of TauT or PAT1 in vitro and does not affect
PAT1 function in vivo in rats (Nohr et al. 2014c), but is
an efficient inhibitor of LAT1 and LAT2 (Soares-da-Silva
and Serrao 2004). In vitro it was clearly shown, that
PAT1 mediated the cellular uptake of taurine and thereby
facilitated the transepithelial taurine transport, which
could be inhibited by Pro and Sar, but not BCH. Based
on in vivo and in vitro mechanistic studies we can sup-




Caco-2 cells were obtained from DSMZ (Deutsche Samm-
lung von Mikroorganismen und Zellkulturen) (Braun-
schweig, Germany). Cell culture plastic ware was obtained
from Corning Life Sciences (Tewksbury, MA, USA).
Taurine (Tau), L-proline (Pro), 2-Amino-2-norbornane-
carboxylic acid (BCH), sarcosine (Sar), Triton
X-100, 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic
acid (HEPES), 4-Morpholineethanesulfonic acid (MES),
imidazole-4-acetic acid (IAA) and sodium bicarbonate
were all obtained from Sigma-Aldrich (St. Louis, MO,
USA). Hank’s Balanced Salt Solution (HBSS) with cal-
cium and magnesium was obtained from Gibco by Life
Technologies (Paisley, UK). D-[1-14C]-Mannitol
(57.2 mCi/mmol), [2,2-3H(N)]-Taurine (19.1 Ci/mmol)
were purchased from Perkin Elmer (Waltham, MA, USA).
Scintillation liquid was either OptiPhase Supermix cock-
tail (for in vivo studies) from Perkin Elmer (Waltham,
MA, USA) or Ultima Gold (for in vitro studies) also from
Perkin Elmer (Boston, MA, USA). Ethanol (96%) was
from either Merck (Darmstadt, Germany) or VRW chem-
icals (Darmstadt, Germany). Purified water was used for
the experiments, obtained from either a Milli-Q and Elga
purification system.
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Methods
Cell culture
Polycarbonate membranes (1.12 cm2, 0.4 lm pore size) of
TranswellTM inserts or 24-well cell culture plates (1.90 cm2)
were used as supports for cell cultivation. The Caco-2 cells
were seeded at a density of 1.7 · 105 cells cm2. Experi-
ments were performed 6 days after seeding the Caco-2 cells
cultured on 24 wells plates or performed 13–15 days post-
seeding cells on TranswellTM insert. The cells were main-
tained at 37°C in Dulbecco’s modified Eagle medium
(DMEM) supplied with 10% Fetal Bovine Serum (FBS),
penicillin/streptomycin (10,000 UmL1/10 mgmL1), L-
glutamine (1%), and NonEssential Amino Acids (1%) in
an atmosphere of 5% CO2 and a 90% relative humidity.
The culture medium was changed every 2–3 days.
Transport study buffer solutions
The donor solutions were prepared in Hanks Balanced
Saline Solution (HBSS) buffered to either pH 7.4 or 6.0
using 10 mmol/L HEPES or MES, respectively. HBSS buf-
fer consisted of in mM: CaCl2, 1.26; MgCl2, 0.49; MgSO4,
0.41; KCl, 5.33; KH2PO4, 0.44; NaCl, 138; Na2HPO4,
0.34; D-glucose, 5.56; NaHCO3, 4.17 and contained
10 mmol/L MES at pH 6.0 (HBSS 6.0) or 10 mmol/L
HEPES pH 7.4 (HBSS 7.4). The pH of the buffers was
adjusted with NaOH/HCl using a pH-meter (Mettler
Toledo, FiveEasyTMFE20, Schwerzenbach, Switzerland).
Receiver solutions were HBSS pH 7.4 supplemented with
various amount of NaCl to make the donor and receiver
solution iso-osmotic. Transport buffers with final concen-
tration and osmolarity of BCH (128.9 mmol/L, 370 
30 mOsm), Pro (173.7 mmol/L, 430  34 mOsm), Sar
(224.5 mmol/L, 478  40 mOsm) or a control were pre-
pared with either HBSS pH 7.4 (280  15 mOsm) or
HBSS pH 6.0 (261  28 mOsm). All donor solutions
contained 1 lCi/mL [3H]-taurine (19.1 Ci/mmol,
52 nmol/L) and the solutions prepared in HBSS pH 6.0
contained additionally 0.1 mmol/L nonradiolabeled tau-
rine. Donor solutions also contained 1 lCi/mL [14C]-
mannitol (57.2 mCi/mmol, 17.5 lmol/L) to measure the
paracellular transport. The osmolality was measured with
a Semi-micro Osmometer K-7400 (Knauer, Berlin, Ger-
many), and the receiver solutions were adjusted with
NaCl to make them iso-osmotic with the corresponding
donor solutions.
Taurine uptake in Caco-2 cells
The uptake of taurine was investigated at either pH 6.0 or
pH 7.4 for 5 min to assess the contribution of TauT and
PAT1 to the total taurine uptake. Previous studies have
shown that uptake of PAT1 substrates in Caco-2 cells is
linear for 5 min (Larsen et al. 2008; Nohr et al. 2014b).
The concentration-dependent taurine (1 lCi/mL [3H]-
taurine, 52 nmol/L) uptake at pH 7.4 was measured at
total taurine concentrations of 0.052, 5, 10, 25, 50, and
100 lmol/L in HEPES buffer, pH 7.4. Taurine concentra-
tions of 0.052, 0.1, 2, 5, 10, 25, and 50 mmol/L in MES
buffer were investigated at pH 6.0. The uptake of
52 nmol/L taurine (1 lCi/mL [3H]-taurine) at pH 7.4
was also measured in the presence of 20 mg/mL BCH,
20 mg/mL Sar, 10 mmol/L imidazole-4-acetic acid (IAA),
which was recently identified as a ligand of TauT (Valem-
bois et al. 2017), and 20 mg/mL Pro. The taurine
(0.1 mmol/L, 1 lCi/mL [3H]-taurine) uptake at pH 6.0
was likewise measured in the presence of 20 mg/mL
BCH, 20 mg/mL Sar or either 10 mmol/L of Sar, Pro,
BCH, and IAA.
After the 5 min incubation, the isotope-containing buf-
fer solution was removed and the wells were washed three
times with 500 lL ice-cold HEPES-buffer, pH 7.4. The
cells were detached using 200 lL of 0.1% Triton X-100,
and transferred to scintillation plastic vials and 2 mL of
scintillation cocktail was added. The samples were vor-
texed 10 s and DPM was measured for 10 min using a
liquid scintillation counter (LSC) (Perkin Elmer, Tri-Carb
2900TR).
Transport of taurine across Caco-2 cell
monolayers
Caco-2 cells grown on Transwell filters (1.12 cm2,
0.4 lm) were used for the transport study. The initial
transepithelial electrical resistance (TEER) was measured
to assure that the barrier properties of the monolayer
were intact. Transport was measured from the apical (A)
to the basolateral (B) side. Before starting the experiment,
all solutions were preheated to a temperature of 37°C.
The cells were incubated with prewarmed HBSS 7.4 for at
least 10 min on a mini shaker (220 rpm) from Troemner
(NJ, US) at 37°C to equilibrate the cells prior to the
experiment. Buffer was removed and the appropriate
solutions were applied on the apical and basolateral side
in a volume of 500 lL and 1000 lL, respectively. Sam-
ples, in a volume of 100 lL, were taken from the receiver
solution at 15, 30, 60, 90 and 120 min after starting the
experiment and replaced with 100 lL fresh HBSS 7.4 on
the basolateral side. Donor samples were taken from each
solution containing radiolabeled compound in a volume
of 20 lL at 0 and 120 min. All samples were transferred
directly into scintillation vials. After the experiment, the
TEER value of each monolayer was measured again. To
all samples, 2 mL scintillation liquid was added and
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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vortexed for 10 sec. The amount of radiolabeled com-
pound (as disintegration per minute, DPM) was analyzed
for 10 min using liquid scintillation counter (LSC) (Per-
kin Elmer, Tri-Carb 2900TR).
Formulations for the pharmacokinetic study
Taurine, BCH, proline, and sarcosine were dissolved in
Elga water. Tonicity of the control solution was adjusted
with sodium chloride to approximately 280 mOsmol/L.
The osmolality of the formulation containing BCH was
326 mOsmol/L and the solution containing Pro and Sar
had an osmolality of 394 mOsmol/L. Osmolalities were
measured using a vapor pressure osmometer by Wescor
Vapro model 5520 (Wescor Inc, Logan, Utah, USA). pH
values were measured using PHM220 LAB pH meter by
Radiometer analytical SAS (Lyon, France). The pH was
adjusted with NaOH or HCl to 7.40  0.05. Immediately
before dosing, [3H]-taurine was added to each formula-
tion containing taurine in an activity of 40 lCi/mL.
Taurine pharmacokinetics in
Sprague-Dawley rats
Male Sprague-Dawley rats, weighing approximately 350 g
(287–398 g) on the day of the experiments, were pur-
chased from Charles River Deutschland (Sulzfeld, Ger-
many). The animals were acclimatized for a minimum of
5 days in groups of two and maintained on standard feed
with free access to water. Prior to dosing, the animals
were fasted for 16–20 h with free access to water. The
protocol used for the animal studies was approved by the
institutional animal ethics committee in accordance with
Danish law regulating animal experiments and in compli-
ance with EC Directive 2010/63/EU and the NIH guideli-
nes on animal welfare.
Five groups of four male Sprague-Dawley rats were
dosed with taurine solutions (10, 30, 100, 299, 997 mg/kg,
with 40 lCi/kg [3H]-taurine) orally by gavage (10 mL/kg).
Additionally, three groups of four male Sprague-Dawley
rats were dosed with taurine solutions (1, 10, 30 mg/kg)
intravenously by injection (5 mL/kg) into the tail vein.
Another group of rats was dosed with a formulation con-
taining 30 mg/kg taurine (with 40 lCi/kg [3H]-taurine)
and 200 mg/kg BCH orally by gavage (10 mL/kg). The last
group was dosed with a formulation containing 30 mg/kg
taurine, 200 mg/kg Pro and 200 mg/kg Sar orally by
gavage (10 mL/kg).
Plasma sampling and sample analysis
The blood samples (100–200 lL), collected after adminis-
tration, were drawn from the tail vein and collected into
EDTA coated tubes (Microwette 500 K3E, Sarstedt,
N€umbrecht, Germany) at 5–360 min after administration
(5, 15, 30, 45, 60, 120, 180, 240, 360 min). Plasma was
harvested immediately by 10 min of centrifugation at
4°C, 3600g (Multifuge 1 S-R, Heraeus, Hanau, Germany)
and stored in polypropylene tubes (Pony Vial, PerkinEl-
mer, Waltham, MA, USA) at 20°C until analysed. At
the end of the experiment, animals were sacrificed by
spinal dislocation using a guillotine. Plasma samples were
left to defrost and mixed with 4 mL of liquid scintillation
cocktail. The samples were counted for 3 min on a scin-
tillation counter from Tri-Carb 2900TR.
Data analysis
Transport data was described by Fick0s first law;
J ¼ m
A  t ¼ Papp  C0
where m is the steady-state amount of transported com-
pound over a given absorptive area (A), J is the flux, t is
time and C0 is the starting concentration in the donor
chamber. From the steady-state flux the apparent perme-
ability coefficient (Papp) was calculated.
The total uptake of taurine at pH 6.0 and 7.4 in Caco-
2 cells was described by Michaelis-Menten like kinetics
with a nonsaturable component:
Vo ¼ Vmax  Tau½ 
Km þ Tau½  þ B  ½Tau
where Vo is the initial uptake rate of taurine at a given
[Tau], which is the concentration of taurine in mmol/L
or lmol/L in the donor solution, Vmax is the maximal
uptake rate, Km is the Michaelis constant, and B is a fac-
tor correcting for nonspecific binding of the isotope and
for isotope dilution.
The total carrier-mediated taurine uptake rate at pH
6.0 was described by:
Vo ¼ Vmax;PAT1  Tau½ 
Km;PAT1 þ Tau½  þ
Vmax;TauT  Tau½ 
Km;TauT þ Tau½ 
The pharmacokinetic parameters of intravenously bolus
administered taurine in male Sprague-Dawley rats were
estimated using a two-compartmental model with elimi-
nation from the central compartment:
C tð Þ ¼ A  eat þ B  ebt
where C(t) is the taurine plasma concentration at a given
time point, and A and a and B and b are hybrid con-
stants related to the concentration in the central and
peripheral compartments, respectively, and the rate of
transfer between these. Based on this Vd1, volume of
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distribution in the central compartment 1; Vd2, volume of
distribution in the peripheral compartment 2; AUC, area
under the curve; and K10, the elimination rate from the
central department, were calculated using Phoenix 6.3
version (Pharsight Corporation, A Certara Company,
USA). The pharmacokinetic parameters of orally adminis-
tered taurine in male Sprague-Dawley rats were estimated
noncompartmentally using Phoenix 6.3 version (Phar-
sight Corporation, A Certara Company, USA). Cmax and
tmax were found as mean values of the plasma concentra-
tion profiles within each group. Area under the plasma
concentration versus time profiles (AUC), an expression
of total exposure, were determined with noncompartmen-
tal analysis using the linear trapezoidal rule from time
zero to Cmax and by log linear methods from Cmax to the
last measured plasma concentration and denoted
AUC0-tlast, ke is the first order elimination rate constant
calculated as the slope from the terminal log plasma con-
centration time curve of individual animals. The total
clearance was calculated as dose divided by AUC.
Statistical analysis
Statistical analysis was performed in GraphPad Prism ver-
sion 7.02. The obtained data was analysed for statistical
differences using Nonparametric Kruskal–Wallis followed
by Dunn’s multiple comparison test. The following levels
of significance were assigned: nonsignificant (NS) and
P < 0.05 (*). However, for convenience values were
expressed as mean  SEM.
Results
Concentration-dependent taurine uptake in
Caco-2 cells under neutral and slightly acidic
conditions
To investigate the underlying cellular mechanism for tau-
rine absorption a series of in vitro experiments were con-
ducted in the human intestinal Caco-2 cell model. At first
the uptake was measured with neutral (pH 7.4) and
slightly acidic (pH 6.0) buffer solutions. When the extra-
cellular pH is 7.4 only TauT is mediating taurine uptake,
while when pH is 6.0 both PAT1 and TauT mediate cellu-
lar taurine uptake. The uptake of taurine was measured at
neutral pH conditions at the concentration range of
0.052–100 lmol/L (see Fig. 1A). The uptake was
described by a saturable and nonsaturable process. The
saturable process was described by a Km-value of
5.6  2.6 lmol/L and a Vmax of 4.6  0.8 pmol/
(cm2min), while the nonsaturable component, B, was
0.057106  0.008106 cm/min. In the presence of a
slight pH gradient (pH 6.0) (Fig. 1B), the saturable
taurine uptake process was described by a Km-value of
7.1  2.3 mmol/L and a Vmax of 1559  309 pmol/
(cm2min), while the nonsaturable component, B, was
41106  5106 cm/min.
Taurine uptake in Caco-2 cells in the
presence of BCH, IAA, Pro, and Sar
The uptake of taurine was investigated in Caco-2 cells at
pH 7.4 and pH 6.0 at two different concentration, that is,
0.052 lmol/L and 100 lmol/L, used as conditions were
TauT and PAT1, respectively, dominate cellular uptake of
taurine. With a taurine concentration of 0.052 lmol/L at
pH 7.4, the taurine uptake was not affected by 10 mmol/
L of the PAT1 substrates proline or sarcosine or the non-
PAT1 and non-TauT substrate BCH, whereas the TauT
Figure 1. Concentration-dependent cellular uptake of [3H]-taurine
in Caco-2 cells. (A) The uptake rate of taurine in Caco-2 cells at
37°C in the presence of increasing concentrations of unlabelled
taurine. The buffer used was HBSS containing 10 mmol/L HEPES
adjusted to pH 7.4. (B) The buffer used was HBSS containing
10 mmol/L MES adjusted to pH 7.4. The uptake was measured for
5 min. The concentration of [3H]-taurine was 1 lCimL1 (52 nmol/
L). Each value represents the mean  SEM of four independent cell
passages (n = 4). The solid lines show the fit of the resulting data
to Michaelis-Menten like kinetics.
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inhibitor IAA significantly inhibited the uptake of a tau-
rine to approximately 10% of the control uptake
(Fig. 2A). At pH 6.0 with a donor concentration of tau-
rine of 0.052 lmol/L, the uptake of taurine was not
affected by 10 mmol/L of BCH, and was significantly
inhibited by 10 mmol/L IAA (Fig. 2B). Even though the
uptake has approximately 50% of the control uptake in
the presence of 10 mmol/L Sar and Pro this was not a
2017 | Vol. 5 | Iss. 19 | e13467
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significant reduction with the employed statistical analy-
sis. When the uptake of taurine was measured at pH 6.0
at a higher taurine concentration of 100 lmol/L, the
uptake was not affected significantly by 10 mmol/L BCH
or 10 mmol/L IAA (Fig. 2C). The uptake was, however,
significantly decreased in the presence of 10 mmol/L Sar
or 10 mmol/L Pro (Fig. 2C). The uptake of taurine was
also measured in the presence of inhibitor amounts simi-
lar to the ones dosed in the animal studies, that is,
20 mg/mL under neutral condition (pH 7.4) Sar, but not
20 mg/mL BCH, decreased the uptake of 0.052 lmol/L
taurine (Fig. 5D). Under slightly acidic conditions, pH
6.0, 20 mg/mL Sar and Pro significantly inhibited the tau-
rine uptake at both taurine concentrations (Fig. 2E and
F), whereas 20 mg/mL BCH did not affect taurine uptake
at neither 0.052 lmol/L nor 100 lmol/L (Fig. 2E and F).
The contribution of PAT1 and TauT to the
carrier-mediated taurine uptake
Based on the data presented in the present work, PAT1
did not contribute to taurine uptake at pH 7.4 and the
carrier-mediated uptake at pH 7.4 was attributed to
TauT. At pH 6.0 the uptake of taurine was attributed to
PAT1, due to the concentration range investigated. The
two Michaelis-Menten like expressions were then com-
bined to estimate the total carrier-mediated taurine
uptake at pH 6.0:
V tau ¼
1559 pmolcm2min  Tau½ 
7123lmol=Lþ Tau½  þ
4:6 pmolcm2min  Tau½ 
5:6lmol=Lþ Tau½ 
In Figure 3 the estimated contribution of PAT1 and
TauT to the carrier-mediated uptake of taurine in Caco-2
cells at pH 6.0 is shown in percentages. Based upon this,
it could be estimated that at 52 nmol/L, TauT was
responsible for 78% of the carrier mediated uptake, at
100 lmol/L PAT1 was responsible for 84% of the carrier-
mediated taurine uptake, at 1 mmol/L 98% and, at
10 mmol/L 99.5%.
Transepithelial transport of taurine across
Caco-2 cell monolayers
The transepithelial transport of taurine across Caco-2 cell
monolayers in the absorptive (A-B) direction was investi-
gated under conditions facilitating either TauT or PAT1
mediated transport. The transport of taurine at
0.052 lmol/L in the presence of 20 mg/mL BCH, Pro
and Sar is shown in Figure 4A. The presence of BCH, Sar
or Pro did not significantly decrease the absorptive per-
meability of taurine. Under conditions facilitating PAT1
mediated transport, that is, at a donor taurine concentra-
tion of 100 lmol/L and with a donor pH of 6.0, BCH
did not alter the taurine permeability, while both Sar and
Pro significantly decreased the absorptive taurine perme-
ability, see Figure 4B. To investigate the barrier properties
of Caco-2 cell in the presence of high amino acid concen-
trations TEER values were measured at room temperature
before and after the experiment and mannitol transport
was evaluated during the transport experiment (Table 1).
TEER values decreased during the transport experiment,
Figure 2. Cellular uptake of [3H]-taurine in Caco-2 cells in the presence of amino acids. (A). The uptake rate of taurine in Caco-2 cells at 37°C
in the absence or presence of 10 mmol/L amino acid. The buffer used was HBSS containing 10 mmol/L HEPES adjusted to pH 7.4. The
concentration of [3H]-taurine was 1 lCimL1 (52 nmol/L). (B). The uptake rate of taurine in Caco-2 cells at 37°C in the absence or presence of
10 mmol/L amino acid. The buffer used was HBSS containing 10 mmol/L MES adjusted to pH 6.0. The concentration of [3H]-taurine was
1 lCimL1 (52 nmol/L). (C) The uptake rate of taurine in Caco-2 cells at 37°C in the absence or presence of 10 mmol/L amino acid. The
buffer used was HBSS containing 10 mmol/L MES adjusted to pH 6.0. The concentration of [3H]-taurine was 1 lCimL1 (52 nmol/L)
supplemented with unlabeled taurine to a total concentration of 100 lmol/L. (D) The uptake rate of taurine in Caco-2 cells at 37°C in the
absence or presence of 20 mg/mL amino acid. The buffer used was HBSS containing 10 mmol/L HEPES adjusted to pH 7.4. The concentration
of [3H]-taurine was 1 lCimL1 (52 nmol/L). (E) The uptake rate of taurine in Caco-2 cells at 37°C in the absence or presence of 20 mg/mL
amino acid. The buffer used was HBSS containing 10 mmol/L MES adjusted to pH 6.0. The concentration of [3H]-taurine was 1 lCimL1
(52 nmol/L). (F) The uptake rate of taurine in Caco-2 cells at 37°C in the absence or presence of 20 mg/mL amino acid. The buffer used was
HBSS containing 10 mmol/L MES adjusted to pH 6.0. The concentration of [3H]-taurine was 1 lCimL1 (52 nmol/L) supplemented with
unlabelled taurine to a total concentration of 100 lmol/L. For all conditions, the uptake was measured for 5 min. Each value represents the
mean  SEM of four to seven independent cell passages (n = 4–7). *:P < 0.05
Figure 3. The estimated contribution of the taurine transporter
(TauT) and the proton-coupled amino acid transporter (PAT1) to
carrier-mediated cellular uptake of taurine at pH 6.0 in Caco-2 cell
monolayers.
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most notable at neutral pH in the presence of 20 mg/mL
Sar and Pro (Table 1). This decrease in TEER was also
followed by an increase in mannitol permeability. How-
ever, at pH 6.0 in the apical chamber the different treat-
ment did not alter mannitol transport.
Intravenous administration of taurine to
male Sprague-Dawley rats
Male Sprague-Dawley rats were dosed by intravenous
administration of taurine at three doses of 1, 10, and
30 mg/kg, and the taurine plasma concentration was
monitored over 4 h (see Fig. 5). This gave measured
plasma concentrations in the range of 0.1–63 lgram/mL,
equivalent to 8–504 lmol/L (Fig. 5). The pharmacoki-
netic (PK) profiles were fitted to a two-compartment
model, and the obtained values for A, B, a, and b are
given in Table 2 and the estimated pharmacokinetic
parameters in Table 3. No differences were found between
groups for Vd1, Vd2, K10 or AUC0-∞ normalized for the
dose of taurine. The relative exposure of taurine was thus
similar in the measured plasma concentration interval
and independent of the administered dose over the dose
range investigated.
Oral administration of taurine to male
Sprague-Dawley rats
Taurine was administered orally to male Sprague-Dawley
rats in doses from 10 to 997 mg/kg. The plasma concen-
tration versus time profiles are presented in Figure 6
and for 30 mg/kg taurine in Figure 7. The pharmacoki-
netic parameters (tmax, Cmax, AUC0-tlast and ke) obtained
from the noncompartmental analysis are shown in
Table 4. After a single orally administered dose of tau-
rine, the time to reach maximal plasma concentration
increased from 15 min at the two lowest doses to
30 min at the intermediate doses (not significantly with
the employed test) and finally significantly to 45 min at
the highest dose. The maximal plasma taurine concentra-
tion was found to be in the range of 0.1–643.4 lg/mL.
When the AUC was normalized to the dose, differences
were observed in the AUC over dose as shown in
Table 4 with the ratio increasing as a function of
increased doses.
Oral taurine pharmacokinetics in the
presence of BCH, sarcosine, and proline
The pharmacokinetic profile after oral administration of
taurine (30 mg/kg) was compared to the oral co-admin-
istration of taurine in the presence of 200 mg/kg BCH
or a combination of 200 mg/kg Pro and Sar (Fig. 7 and
Table 5). To administer the dose of 30 mg/kg taurine,
the animals were given a solution of 30 mg per 10 mL,
which corresponded to a taurine concentration of
24 mmol/L. The initial concentration in the gastro-
intestinal system of the rats was thus assumed to be
approximately 24 mmol/L. Co-administration of the
Figure 4. Transepithelial taurine across Caco-2 cell monolayers in
the presence of amino acids. The apparent transepithelial
permeability, Papp, of taurine across Caco-2 cell monolayers from
apical to basolateral side (A–B). The transepithelial transport was
measured for 120 min and the permeability was calculated under
steady-state conditions from Ficks first law and expressed as
mean  SEM of measurements performed in three to four
independent cell passages (n = 3–4). (A) Apical and basolateral pH
was 7.4 for [3H]-taurine (1 lCi/mL [3H]-taurine, 52 nmol/L)
permeability across Caco-2 cell monolayers in the absence or
presence of 20 mg/kg BCH (128.9 mmol/L), proline (173.7 mmol/L)
or sarcosine (224.5 mmol/L). (B) Apical pH was 6.0 and basolateral
pH was 7.4 for 100 lmol/L taurine (1 lCi/mL [3H]-taurine,
52 nmol/L) permeability across Caco-2 cell monolayers in the
absence or presence of 20 mg/kg BCH (128.9 mmol/L), proline
(173.7 mmol/L) or sarcosine (224.5 mmol/L). *: P < 0.05
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PAT1 substrates, Pro and Sar, significantly altered the
taurine PK profile by reducing the maximal plasma con-
centration, Cmax, and increasing the time to reach this,
tmax, whereas the overall exposure (AUC) remained
unchanged. The taurine plasma concentration versus
time profiles after co-administration of the non-PAT1
ligand BCH was similar to the taurine profile in the
absence of co-administered amino acid.
Discussion
In this study, we investigated intestinal taurine absorp-
tion and taurine pharmacokinetics at different doses,
and investigated taurine disposition after intravenous
administration. The mechanism behind intestinal taurine
absorption was investigated using an in vivo co-admin-
istration approach and in vitro experiments in Caco-2
cells. The main findings were that oral taurine absorp-
tion was not saturable with increasing taurine doses,
and that the time to reach the maximal plasma concen-
tration increased with dose and after administration
with PAT1 substrates. Since the absorption could be
delayed and reduced with PAT1 substrates this all point
toward a role of PAT1 in mediating the intestinal
absorption of taurine. The implication is that the intes-
tine is capable of absorbing large amount of taurine
after a single dose or intake. It appears, that 30 mg/kg
taurine could be a standard substrate dose for pharma-
cokinetic studies investigating changes in intestinal
PAT1 transport activity after physiological or pharmaco-
logical regulation or for investigating the possibility of
drug/drug or drug/nutrient interactions at the level of
intestinal transport.
Taurine absorption was facilitated by PAT1
in vitro
The intestinal transport mechanism of taurine was inves-
tigated in Caco-2 cells. Firstly, the uptake of taurine into
Caco-2 cells was investigated at neutral extracellular pH
(pH 7.4) and slightly acidic pH (pH 6.0). Taurine trans-
port via TauT is sodium- and chloride-dependent and
proton-independent, whereas transport via PAT1 is pro-
ton-dependent and sodium- and chloride-independent
(Anderson et al. 2009). We therefore used pH, taurine
concentration and PAT1 and TauT inhibitors to distin-
guish between PAT1 and TauT mediated uptake, while
maintaining physiological concentrations of sodium and
chloride. Anderson et al. (2009) have earlier investigated
taurine uptake in Caco-2 cells using a different strategy
where the PAT1-mediated taurine uptake was measured
at an extracellular pH of 5.5 in the absence of sodium
and TauT-mediated transport was shown by the reduced
uptake at pH 7.4 in the absence of sodium or chloride
ions. Taurine uptake, in our study, under neutral pH
condition showed saturable kinetics with a Km-value of
5.6 lmol/L and under slightly acidic (pH 6.0) conditions
with a sodium-containing buffer we found a Km-value of
7.1 mmol/L. In the absence of sodium in the uptake buf-
fer and at pH 5.5 Anderson found a Km-value of
10.1 mmol/L. Considering the different Km-values of tau-
rine and the difference in driving force, we attribute the
uptake measured at pH 7.4 to TauT only, and could
therefore estimate that at slightly acidic pH of 6.0, PAT1
was the dominating transporter at taurine concentrations
above 15 lmol/L. Anderson et al. (2009) have previously
shown similar conclusions in Caco-2 cells estimated as
Table 1. Apparent transepithelial permeability of [14C]-mannitol and transepithelial electrical resistance (TEER) values of Caco-2 cell
monolayers.





Before After Before After
Control 0.9 x 107  9.3 x 109 541  40 421  31 1.1 x 107  3.4 x 108 489  49 472  9
+ BCH (20 mg/mL) 1.6 x 107  7.6 x 109 512  40 299  28 1.4 x 107  1.3 x 108 491  54 349  57
+ Pro (20 mg/mL) 3.4 x 107  7.5 9 108 (*) 486  62 135  23 1.7 x 107  1.3 x 108 509  64 354  56
+ Sar (20 mg/mL) 3.2 x 107  7.9 9 108 (*) 467  48 171  53 1.8 x 107  1.6 x 108 514  54 401  69
The apparent transepithelial permeability, Papp, of 1 lCi/mL [
14C]-mannitol (57.2 mCi/mmol, 17.5 lmol/L) mannitol across Caco-2 cell mono-
layers from apical to basolateral side (A–B) obtained under the conditions shown in Figure 7. The transepithelial transport was measured for
120 min and the permeability was calculated under steady-state conditions from Fick0s first law and expressed as mean  SEM of measure-
ments performed in three to four independent cell passages (n = 3–4). A–B transport pH 7.4/7.4: Apical and basolateral pH was 7.4 for con-
trol ([3H]-taurine (1 lCi/mL [3H]-taurine, 52 nmol/L)) and the presence of 20 mg/kg BCH (128.9 mmol/L), proline (173.7 mmol/L) or sarcosine
(224.5 mmol/L). A–B transport pH 6.0/7.4: Apical pH was 6.0 and basolateral pH was 7.4 for control (100 lmol/L taurine, 1 lCi/mL [3H]-taur-
ine) and presence of 20 mg/kg BCH (128.9 mmol/L), proline (173.7 mmol/L) or sarcosine (224.5 mmol/L). *:P < 0.05.
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differences in the chloride-dependent uptake of taurine at
an extracellular pH of 6.5.
To further understand the mechanism for intestinal
taurine absorption, we measured the uptake of taurine at
52 nmol/L and 100 lmol/L at neutral and slightly acidic
pH in the presence of different concentrations of BCH,
Sar, Pro as well as IAA. At neutral pH, with 52 nmol/L
of taurine, the uptake was via TauT, and was not inhib-
ited by 10 mmol/L of BCH, Pro or Sar, but inhibited by
20 mg/mL BCH and Sar. Since 10 mmol/L BCH and Sar
had no effect on taurine uptake, the inhibitory effect at
the higher concentration was likely caused by the high
osmolarity of the solutions. It is important to note that
the uptake studies were conducted on cells cultured on
plastic ware and not on filter support. The consequence
is that the cells are not exposed to a basolateral medium
for equilibration and solute transport. Therefore, the
osmotic effect is less on filter-grown cells and in situations
were more solute is transported into the cells, as under
slightly acidic conditions were PAT1 transports taurine.
A recently identified ligand of TauT, IAA (Valembois
et al. 2017), inhibited the taurine uptake at neutral pH
and slightly acidic pH at 52 nmol/L taurine, but not at
100 lmol/L, pH 6.0 where PAT1 was dominating. It was
an interesting finding that IAA may be a selective TauT
inhibitor, since most substrates of TauT such as, for
example, taurine, GABA, and b-Ala are also substrates of
PAT1 (Frølund et al. 2013). However, this need further
clarification using PAT1-expression systems. The inhibi-
tor studies showed that 20 mg/mL BCH is not likely to
inhibit taurine transport via TauT or PAT1, and that
20 mg/mL Sar and Pro will inhibit uptake via PAT1
without any effect on TauT mediated uptake. To confirm
that cellular influx via PAT1 resulted in actual transep-
ithelial intestinal transport, the transport of taurine
across Caco-2 cell monolayers was measured. Under con-
ditions designed to evaluate TauT mediated transport
(Fig. 7A) of taurine, 20 mg/mL BCH, Sar or Pro did not
alter transepithelial taurine transport. Under conditions
Figure 5. Taurine PK curves after IV administration to male
Sprague-Dawley rats. Taurine plasma concentration versus time
profiles following intravenous administration of [3H]-taurine
(40 lCi/kg) to a total dose of 1.0 mg/kg (A), 10 mg/kg (B) or
30 mg/kg (C) taurine. The data was fitted to a two-compartmental
model C tð Þ ¼ A  eat þ B  ebt . Data is presented as mean  SEM
of measurements from 4 to 8 rats per dosing group.
Table 2. Pharmacokinetic parameters for two-compartment
pharmacokinetics after intravenous administration of taurine at
three doses of 1, 10, and 30 mg/kg to male Sprague-Dawley rats.
Taurine
dose
(mg/kg) A (lg/mL) B (lg/mL) a (1/min)
b (1/min) *
103
1 3.5  0.5 0.12  0.03 0.14  0.02 1.9  0.4
10 31.0  4.2 0.89  0.14 0.144  0.03 3.0  0.9
30 99.9  15.5 1.87  0.45 0.07  0.01 1.3  0.6
Data is presented as mean  SEM of measurements from 4 to 6
rats per dosing group
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Page 10
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Intestinal PAT1-Mediated Taurine Absorption C. U. Nielsen et al.
aimed at evaluating PAT1 mediated transport, BCH did
not affect permeability, whereas 20 mg/mL Sar and Pro
clearly reduced the transepithelial transport of taurine.
Thus, influx of taurine via PAT1 resulted in facilitating
transepithelial transport and inhibition of PAT1 reduced
this transport.
Table 3. Pharmacokinetic parameters of taurine after intravenous administration to male Sprague-Dawley rats.
Taurine dose




(lgmin/mL pr. mg/kg) K10 (1/min)
1 11.7  1.30 299  48 4608  974 89  9 89  18.9 0.04  0.01
10 18.7  2.54 353  62 4662  1153 587  77 59  19.0 0.06  0.01
30 9.4  1.42 323  63 8374  4466 3452  588 115  39.2 0.03  0.01
Rats were intravenously administered 40 lCi/kg [3H]-taurine with the total doses indicated. Data are expressed as mean  SEM of measure-
ments from 4 to 8 rats per dosing group. CL, clearance; Vd1, volume of distribution in compartment 1; Vd2, volume of distribution in compart-
ment 2; AUC, area under the curve; K10, the elimination rate from the central department.
Figure 6. Taurine PK curves after oral administration of taurine to male Sprague-.Taurine plasma concentration versus time profiles following
oral administration of [3H]-taurine (40 lCi/kg) and, 10 mg/kg, 100 mg/kg, 299 mg/kg or 997 mg/kg taurine. Data is presented as mean  SEM
of measurements from four rats per dosing group.
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Taurine absorption and exposure after oral
and intravenous administration
The pharmacokinetic profile after intravenous administra-
tion could be described by a two-compartment model
with first-order rate constants and elimination from the
central compartment. The different doses did not result in
significant differences in taurine clearance or in dose-nor-
malized exposure. The clearance in this study was approxi-
mately 9–18 mL/min/kg (0.56–1.1 L/h/kg), whereas the
clearance in Sprague-Dawley rats dosed with 20 mg/kg
was reported to be 0.13–0.15 L/h/kg (Tang et al. 2014),
thus lower than in the present study. In beagle dogs a
clearance of 0.20 L/h/kg have been reported (Yu et al.
2013), which was also lower than the values obtained here.
In the present study, a compartmental analysis was used
for the evaluation of the plasma data, whereas the two
mentioned studies used noncompartmental analysis.
Taurine was furthermore dosed orally in increasing
doses ranging from 10 to 997 mg/kg. As dose increased,
AUC0-tlast increased as well, but a linear correlation was
not observed. In fact, the AUC0-tlast increased more with
increasing dose. If intestinal absorption is saturated a
decrease in dose normalized AUC is expected, as clearly
shown with the drug substance gabapentin, which is a
substrate for an intestinal carrier with a low transport
capacity (Larsen et al. 2015). For gabapentin, a clear
dose-dependent absorption in Sprague-Dawley rats was
observed with a decreasing AUC over dose with increas-
ing doses due to saturation of the absorption step (Larsen
et al. 2015). IV administration of three different doses of
taurine did not reveal any changes in clearance as dis-
cussed above, hence a possible explanation for the lack of
Figure 7. Taurine PK curves after oral administration of 30 mg/kg
taurine to male Sprague-Dawley rats in the presence of amino
acids. Taurine plasma concentration versus time profiles after oral
co-administration of [3H]-taurine (40 lCi/kg) and taurine (30 mg/
kg) (control) or with 200 mg/kg BCH or a combination of 200 mg/
kg Pro and Sar. Data is presented as mean  SEM of
measurements from 4 to 8 rats per dosing group.
Table 4. Pharmacokinetic parameters of taurine after oral administration to male Sprague-Dawley rats.
Taurine




(lgmin/mL pr. mg/kg) ke (1/min)
10 15.0 [15.0; 26.25] 2.0  0.2 213  13 21  1.3 0.004  0.001
30 15.0 [15.0; 26.25] 15.7  2.4 1116  134 37  4.5 0.007  0.001
100 30.0 [30.0; 30.0] 70.0  6.5 5396  601 54  6.0 0.010  0.0001
299 30.0 [30.0; 30.0] 227.8  16.0 18400  2001 62  6.7 0.010  0.001
997 45.0 [45.0; 56.25] 643.4  81.0 79118  6692 79  6.7 0.009  0.0009
Rats were orally administered 40 lCi/kg [3H]-taurine and taurine in various doses. The pharmacokinetic parameters Cmax, AUC and ke are
expressed as mean  SEM, while tmax is expressed as the median [Q1; Q3] (25% and 75% percentile) of measurements from 4 rats per dosing
group. tmax, time to reach maximum concentration; Cmax, the maximum concentration; ke, elimination rate constant.
Table 5. Pharmacokinetic parameters of 30 mg/kg taurine after oral co-administration with BCH or Pro and Sar to male Sprague-Dawley rats.
Taurine
(mg/kg) BCH (mg/kg) Sar (mg/kg) Pro (mg/kg) tmax (min) Cmax (lg/mL)
AUC0-tlast
(lgmin/mL)
30 – – – 15.0 [15.0; 15.0] 15.6  1.0 1181  62
30 200 – – 15.0 [15.0; 15.0] 15.5  0.6 1234  91
30 – 200 200 37.5* [30.0; 45.0] 8.5  1.7* 1324  153
Rats were orally administered 30 mg/kg taurine alone or with BCH (200 mg/kg) or a combination of proline and sarcosine (200 mg/kg). The
pharmacokinetic parameters Cmax and AUC are expressed as mean  SEM, while tmax is expressed as the median [Q1; Q3] (25% and 75%
percentile) of measurements from 4 to 8 rats per dosing group. * significantly different from administration of taurine alone.
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dose linearity could be saturation of the accumulation of
taurine in tissues such as kidney, brain and eye, which
would result in an increased taurine plasma concentra-
tion. Another explanation could be a limitation of elimi-
nation, however, when examining the elimination rate
constants, estimated via a noncompartmental analysis, an
increase was not observed as the dose increased. Thus, a
limitation in elimination most likely would not be the
cause of the lack of dose proportionality. Sved et al.
(2007) have previously presented pharmacokinetic pro-
files, where 30 mg/kg and 300 mg/kg taurine were admin-
istered orally to male Sprague-Dawley rats. The AUC
values obtained were 236 lg·h/mL and 1760 lg·h/mL,
respectively. Compared to the AUC0-tlast values obtained
in this study of 1116  134 lg·min/mL (30 mg/kg) and
18400  2001 lg·min/mL (299 mg/kg), the values pre-
sented by Sved et al. (2007) were larger. An explanation
could be in the pharmacokinetic analysis, where Sved
et al. have extrapolated AUC to infinity due to a longer
sampling period. The pharmacokinetic profile of taurine
has also been examined after oral administration in
humans (Ghandforoush-Sattari et al. 2010). Taurine was
administered in a dose of 4 g, correlating to 50 mg/kg
with a median volunteer weight of 79.5 kg. The elimina-
tion rate constant was comparable to the value presented
in this study, but Cmax, tmax, and AUC0-tlast estimated in
humans were all higher, when compared to doses of 30
and 100 mg/kg in rats. Collectively, the presented study
has demonstrated that the disposition of taurine was not
saturable at IV doses and plasma concentrations shown,
and that oral taurine absorption was not saturable with
increasing dosing, yet had increased time to reach maxi-
mal plasma concentration with increasing dose. The latter
is an indication of carrier-mediated absorption via a car-
rier with a high transport capacity and an expression
along the length of the intestine.
Taurine was administered to male Sprague-Dawley rats
at a dose of 30 mg/kg, corresponding to an initial intestinal
concentration of 24 mmol/L, in combination with 20 mg/
mL BCH, Pro and Sar to male Sprague-Dawley rats. The
dose chosen was comparable to the concentration found in
common “High Energy” drinks, and clearly much higher
than the concentration required to saturate TauT mediated
transport. The presence of BCH, which is not a substrate
of TauT or PAT1 in vitro and does not affect PAT1 func-
tion in vivo in rats (Nohr et al. 2014c), did not have any
significant effect on any of the pharmacokinetic parameters
AUC0-tlast, tmax, and Cmax. However, when taurine was co-
administrated with proline and sarcosine, both PAT1 sub-
strates, a significant increase in tmax and a decrease in Cmax
was observed, without an effect on AUC0-tlast. We have pre-
viously shown a similar pattern for gaboxadol absorption
in rats and dogs, and for vigabatrin in rats (Larsen et al.
2009; Broberg et al. 2012; Nohr et al. 2014c), and attribu-
ted this to carrier-mediated intestinal absorption via PAT1.
It is known, that several factors have an impact on the gas-
tric emptying rate. Particularly the intake of high-calorie
meals decreases the gastric emptying rate with a near-to
linear correlation (Calbet and MacLean 1997). The effect
observed on Cmax and tmax, after co-administration of tau-
rine with proline and sarcosine, could therefore also reflect
the influence on the gastric emptying rate and not be
related to amino acid mediated inhibition of absorption
via PAT1. However, BCH did not alter the PK profile of
taurine, and we have previous shown that that 200 mg/kg
sarcosine do not alter the gastric emptying rate in rats
(Nohr et al. 2014c). High doses of amino acids were used
since the intestinal transport capacity of PAT1 is difficult
to saturate due to the expression along the small intestine
and the high transport capacity of PAT1 (Broberg et al.
2012; Nohr et al. 2015) that due to gastrointestinal transit
enables absorption of high doses.
In conclusion, the presented study has shown that tau-
rine disposition in rats was unaltered at the doses investi-
gated. After oral taurine administration, it was not
possible to saturate taurine absorption, suggesting a large
intestinal absorptive capacity. In vitro and in vivo data in
this study supported that the high taurine clearance from
the intestine may be explained by the intestinal transport
of taurine via the low-affinity high-capacity amino acid
transporter, PAT1.
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